Durvalumab and Eribulin in Her2-negative Metastatic Breast Cancer and Recurrent Ovarian Cancer

NCT03430518 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

9

Enrollment

OTHER

Sponsor class

Conditions

HER2-Negative Metastatic Breast Cancer
Recurrent Ovarian Cancer

Interventions

DRUG: Durvalumab
DRUG: Eribulin

Sponsor

Amy Tiersten

Collaborators

[object Object]
[object Object]